Extrinsic Apoptosis Pathway Altered by Glycogen Synthase Kinase-3 beta Inhibitor Influences the Net Drug Effect on NSC-34 Motor Neuron-Like Cell Survival

Abstract

Glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors have been suggested as a core regulator of apoptosis and have been investigated as therapeutic agents for neurodegenerative diseases, including amyotrophic lateral sclerosis. However, GSK-3 beta has an interesting paradoxical effect of being proapoptotic during mitochondrial-mediated intrinsic apoptosis but antiapoptotic during death receptor-mediated extrinsic apoptosis. We assessed the effect of low to high doses of a GSK-3 beta inhibitor on survival and apoptosis of the NSC-34 motor neuron-like cell line after serum withdrawal. Then, we identified changes in extrinsic apoptosis markers, including Fas, Fas ligand, cleaved caspase-8, p38 alpha, and the Fas-Daxx interaction. The GSK-3 beta inhibitor had an antiapoptotic effect at the low dose but was proapoptotic at the high dose. Proapoptotic effect at the high dose can be explained by increased signals in cleaved caspase-8 and the motor neuron-specific p38 alpha and Fas-Daxx interaction. Our results suggest that GSK-3 beta inhibitor dose may determine the summation effect of the intrinsic and extrinsic apoptosis pathways. The extrinsic apoptosis pathway might be another therapeutic target for developing a potential GSK-3 beta inhibitor.